Table 2

Patient demographics, MRI results, and biopsy results

Total patients33
 Patients with any prostate cancer, n (%)18 (54.6)
 Patients with clinically significant prostate cancer, n (%)8 (24.2)
Median (IQR) prebiopsy PSA level, ng/mL7.0 (5.1–11.4)
Median (IQR) prebiopsy prostate volume, mL47 (39–66)
Median (IQR) age, years67 (59–71)
Race/ethnicity, n (%)
 Decline11 (33.3)
 White11 (33.3)
 Black2 (6.1)
 Asian3 (9.9)
 Other6 (18.2)
Clinical history, n (%)
 Biopsy naïve14 (42.4)
 Active surveillance6 (18.2)
 Prior negative biopsy10 (30.3)
 Post-partial gland cryoablation3 (9.1)
Median (IQR) systematic cores taken9 (2–12)
Median (IQR) targeted cores taken4 (2–6)
Tumor characteristics
Number of ROIs, total47
MRI Grades (PI-RADS v2 Score), total, n (%)
 316 (34.0)
 425 (53.2)
 56 (12.8)
Highest Gleason Grade Group, n (%)
 Benign15 (45.6)
 110 (30.3)
 26 (18.2)
 31 (3.0)
 40 (0)
 51 (3.0)
Complications, n (%)3 (9.1)
 Hematuria2 (6.1)
 Urinary retention1 (3.0)
  • PI-RADS, Prostate Imaging-Reporting and Data System; PSA, prostate specific antigen.